November 9, 2010 Brevard, NC USA:

PharmAgra Labs, Inc. (Brevard, NC) and Lalilab Inc. (Durham, NC) are pleased to announce that their Stabilized Sulforaphane patent application (2008-0176942) has received a Notice of Allowance from the United States Patent Office indicating that the patent will be granted in the United States. Patent applications in other major geographies are pending.

The patent will contain method and compositional claims around the use of cyclodextrins to stabilize sulforaphane and its analogues.

Evgen Limited (United Kingdom) has obtained an Option Agreement to license, on a world-wide exclusive basis, stabilized sulforaphane (Sulforadex®) for medical applications. The initial target is to develop a low cost, safe for long-term use, medicine for patients diagnosed with indolent forms of prostate cancer – the objective being to significantly reduce the risk of disease progression during an active surveillance program, thereby delaying or removing the requirement for a radical procedure such as a prostatectomy.

The cancer preventative benefit of cruciferous vegetables (such as broccoli) is widely believed to be due to a molecule called glucoraphanin, which upon consumption converts to the bioactive molecule sulforaphane. While sulforaphane has been well studied with regard to its mechanism of action in chemoprevention1, 2, it has been an unrealistic drug candidate due to poor stability and a lack of intellectual property. The granting of this patent is a major milestone in the commercialization of this most promising molecule.

Chief Executive of Evgen, Dr Stephen Franklin said:

“Evgen, PharmAgra Labs and Lalilab are delighted with this positive development. We are currently in the process of raising the investment capital required to advance Sulforadex® into the clinic, and this news is going to be pivotal to closing this funding round. We believe we now have the scope of protection and patent life required to underpin what we believe is a relatively low risk drug development program in an area with enormous unmet clinical need”.

For more information, please feel free to contact Roger Frisbee (PharmAgra Labs, Inc., 828-884-8656) or Michel Baudet (Lalilab, Inc., 919-620-6767).

1 Glucosinolates, isothiocyantes and human health. Traka M. and Mithen R. F. (2009) Phytochem Rev 8 (1); 269-282
2Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP Mice in association with increased cytotoxicity of Natural Killer Cells. Singh, S. V et al (2009) Cancer Res 69: (5); 2117-2125